Search
AdimrSC-2f
go.drugbank.com/drugs/DB16436InvestigationalThe AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].
Sipagladenant
go.drugbank.com/drugs/DB17080InvestigationalKW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822]
GX-19 Vaccine
go.drugbank.com/drugs/DB15891InvestigationalThe GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758]. … As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].
Edivoxetine
go.drugbank.com/drugs/DB09184InvestigationalEdivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant … Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.
Fasinumab
go.drugbank.com/drugs/DB12157Investigational[A241165] NGF was first discovered in the 1950s[A241180] and was the first neurotrophic factor to be identified and biochemically characterized. … It is currently under investigation for the treatment osteoarthritic pain[A241045] and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e
Categories: Analgesics, Non-NarcoticTranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalTranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring.
Categories: Monoamine Oxidase Inhibitors, Non-Selective, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAmitraz
go.drugbank.com/drugs/DB11373ExperimentalVet approvedAmitraz is a non-systemic acaricide and insecticide. It was generated in 1969 by the Boots Co. in England. … Its insecticide effect is due to its agonistic activity in the alpha-adrenergic system, its interaction with the octopamine receptors in the central nervous system and its driven inhibition of the synthesis
Synonyms: N,N'-(methyliminodimethylidyne)bis-2,4-xylidineSYNB1353
go.drugbank.com/drugs/DB17666Investigational[A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. … It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion into homocysteine.[L45983]
Tildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalA study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257]. … The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Piperidione
go.drugbank.com/drugs/DB13224ExperimentalPiperidione was cough medicine marketed by Roche under the trade name Sedulon.